BioStem (BSEM) COO Andrew Smith‑Van Vurst Exercises Options

What Happened

• Andrew Smith‑Van Vurst, Chief Operating Officer of BioStem Technologies (BSEM), reported exercising stock option/derivative interests in two transactions: 7,622 shares on September 15, 2026 and 9,574 shares on September 17, 2026 — a total of 17,196 shares. The Form 4 lists the exercise/conversion price as $0.00 and reports no cash value for these entries (total reported cash value $0).

Key Details

• Transaction dates and reported price: Sep 15, 2026 (7,622 shares @ $0.00); Sep 17, 2026 (9,574 shares @ $0.00).
• Transaction code: M (option exercise/conversion of a derivative).
• Shares owned after transaction: not specified in the materials provided.
• Footnotes: F1 indicates the options are fully vested and exercisable. Other listed footnotes (F2–F8) describe various vesting schedules and RSU mechanics (F5 notes each RSU equals one share).
• Filing timeliness: Form filed 2026-09-17 for transactions on 2026-09-15 and 2026-09-17; no indication in the provided data that the filing was late.
• Exhibit noted: Exhibit 24 — Power of Attorney.

Context

• The filing records both “acquired” and matching “disposed” derivative entries for the same share amounts on the respective dates, and reports $0.00 for the price—indicating an exercise/conversion event in the derivative instrument. The Form 4 does not report open‑market sale proceeds or prices, so it does not show a market sale of the resulting shares.
• For retail investors: exercises convert options into shares (or settle derivative rights) but do not necessarily signal a buy or sell decision in the open market unless subsequent sale transactions are reported.